A Phase I/II Study of TJ004309 for Advanced Solid Tumor

Summary

This study is a phase I/II study of single drug TJ004309 and Toripalimab combine treatment for Advanced solid tumor. This study include two stages. First stage is dose escalation and second stage is dose extension. The purpose of part A is to confirm the MTD or MED and the clinical dose. The purpose of part B is to observe the safety, effectiveness, Pharmacokinetics, pharmacodynamics and biomarker properties for effective subjects.

Timeline

Start

2020-05-09

Primary completion

2025-04-30

Completion

2025-04-30

Drugs

Indications